Results 21 to 30 of about 7,761,768 (249)

Drug-Drug-Gene Interactions in Cardiovascular Medicine. [PDF]

Pharmgenomics Pers Med, 2022
Cardiovascular disease remains a leading cause of both morbidity and mortality worldwide. It is widely accepted that both concomitant medications (drug–drug interactions, DDIs) and genomic factors (drug–gene interactions, DGIs) can influence ...
Asiimwe IG, Pirmohamed M.
europepmc   +2 more sources

Drug-drug-gene interactions and adverse drug reactions. [PDF]

Pharmacogenomics J, 2020
The economic and health burden caused by adverse drug reactions has increased dramatically in the last few years. This is likely to be mediated by increasing polypharmacy, which increases the likelihood for drug-drug interactions.
Malki MA, Pearson ER.
europepmc   +2 more sources

The impact of CYP2C19 genotype on phenoconversion by concomitant medication

Frontiers in Pharmacology, 2023
Introduction: Pharmacogenetics-informed drug prescribing is increasingly applied in clinical practice. Typically, drug metabolizing phenotypes are determined based on genetic test results, whereupon dosage or drugs are adjusted.
Laura M. de Jong, Soukayna Boussallami, Elena Sánchez-López, Martin Giera, Maarten E. Tushuizen, Menno Hoekstra, Lukas J. A. C. Hawinkels, Robert Rissmann, Robert Rissmann, Robert Rissmann, Jesse J. Swen, Martijn L. Manson   +11 more
doaj   +1 more source

Drug-Drug-Gene Interactions: A Call for Clinical Consideration [PDF]

, 2021
It is widely accepted that both comedications and genetic factors may contribute to variation of drug response. Clinical decision support systems increasingly consider recommendations on drug– drug interactions (DDIs) during electronic prescribing, and ...
Cascorbi, Ingolf, Ingolf Cascorbi, Henrike Bruckmueller, Bruckmüller, Henrike   +3 more
core   +1 more source

Prediction of Drug–Drug–Gene Interaction Scenarios of (E)-Clomiphene and Its Metabolites Using Physiologically Based Pharmacokinetic Modeling

Pharmaceutics, 2022
Clomiphene, a selective estrogen receptor modulator (SERM), has been used for the treatment of anovulation for more than 50 years. However, since (E)-clomiphene ((E)-Clom) and its metabolites are eliminated primarily via Cytochrome P450 (CYP) 2D6 and ...
Christina Kovar, Lukas Kovar, Simeon Rüdesheim, Dominik Selzer, Boian Ganchev, Patrick Kröner, Svitlana Igel, Reinhold Kerb, Elke Schaeffeler, Thomas E. Mürdter, Matthias Schwab, Thorsten Lehr   +11 more
doaj   +1 more source

Comparison of Multidrug Use in the General Population and among Persons with Diabetes in Denmark for Drugs Having Pharmacogenomics (PGx) Based Dosing Guidelines

Pharmaceuticals, 2021
Background: This study measures the use of drugs within the therapeutic areas of antithrombotic agents (B01), the cardiovascular system (C), analgesics (N02), psycholeptics (N05), and psychoanaleptics (N06) among the general population (GP) in comparison
Niels Westergaard, Lise Tarnow, Charlotte Vermehren   +2 more
doaj   +1 more source

CYP2D6 drug-gene and drug-drug-gene interactions among patients prescribed pharmacogenetically actionable opioids. [PDF]

Appl Nurs Res, 2017
Purpose When codeine and tramadol are used for pain management, it is imperative that nurses are able to assess for potential drug-gene and drug-drug-gene interactions that could adversely impact drug metabolism and ultimately pain relief.
Knisely MR, Carpenter JS, Draucker CB, Skaar T, Broome ME, Holmes AM, Von Ah D.   +6 more
europepmc   +2 more sources

DGIdb 2.0: mining clinically relevant drug-gene interactions. [PDF]

Nucleic Acids Res, 2016
The Drug–Gene Interaction Database (DGIdb, www. dgidb.org) is a web resource that consolidates dis-parate data sources describing drug–gene interac-tions and gene druggability.
Wagner AH, Coffman AC, Ainscough BJ, Spies NC, Skidmore ZL, Campbell KM, Krysiak K, Pan D, McMichael JF, Eldred JM, Walker JR, Wilson RK, Mardis ER, Griffith M, Griffith OL.   +14 more
europepmc   +2 more sources

The Effect of Genotyping on the Number of Pharmacotherapeutic Gene–Drug Interventions in Chronic Kidney Disease Patients

Pharmacy, 2023
Patients with chronic kidney disease (CKD) stage 3–5 are polypharmacy patients. Many of these drugs are metabolized by cytochrome P450 (CYP450) and CYP450. Genetic polymorphism is well known to result in altered drug metabolism capacity.
Catharina H. M. Kerskes, Carien J. M. E. van den Eijnde, Albert-Jan L. H. J. Aarnoudse, René J. E. Grouls, Birgit A. L. M. Deiman, Maarten J. Deenen   +5 more
doaj   +1 more source

DeSIDE-DDI: interpretable prediction of drug-drug interactions using drug-induced gene expressions

Journal of Cheminformatics, 2022
Adverse drug-drug interaction (DDI) is a major concern to polypharmacy due to its unexpected adverse side effects and must be identified at an early stage of drug discovery and development.
Eunyoung Kim, Hojung Nam
doaj   +1 more source